We 'swapped' one of our contracted sites over a year ago we follow up
questionnaires at 6 & 12 months - nothing found as yet!
Amanda Savage
Specialist Practitioner Occupational Health
University Hospitals Birmingham NHS Trust
Tel: 0121 627 8286
[log in to unmask]
This email and any files transmitted with it are confidential and intended
solely for the use of the individual or entity to whom they are addressed.
If you have received this email in error please notify the sender.
University Hospital Birmingham cannot accept any responsibility for the
accuracy or completeness of this message, and does not authorise any
contract to be made using the Internet
> -----Original Message-----
> From: Swann, Alan B [SMTP:[log in to unmask]]
> Sent: 28 April 2003 10:04
> To: [log in to unmask]
> Subject: Re: Cidex OPA- surveillance
>
> Have those carrying out surveillance found anything?
> How many are under surveillance. What has been the outcome?
>
> Dr. Alan Swann, BM, AFOM
> Director of Occupational Health
> Occupational Health Service
> Imperial College London
> Southside building
> South Kensington Campus
> London
> SW7 1 LU
> Tel: +44 (20) 7594 9385
> Fax: +44 (20) 7594 9407
> http://www.ad.imperial.ac.uk/occ_health/
>
>
>
>
> -----Original Message-----
> From: Alison Brewster [mailto:[log in to unmask]]
> Sent: 28 April 2003 10:01
> To: [log in to unmask]
> Subject: Re: Cidex OPA- surveillance
>
> Hi,
>
> In our NHS Trust, we have continued the same health surveillance for
> Cidex OPA that we were doing for Gluteraldehyde - i.e baseline
> questionnaires and lung functions and then periodic questionnares -
> further lung functions if any possible symptoms.
>
> Alison Brewster
> Occupational Health Sister
> Southampton University Hospitals NHS Trust
>
> >>> [log in to unmask] 04/28/03 09:05am >>>
> We have recieved notification from HSE via our H&S manager that there
> is
> some limited indication that alternatives to glutaraldehyde (ie active
> ingredients OPA and SDA) may hold similar health effects following
> exposure
> ie potential to cause occupational asthma, and recommends that control
> strategies be put in place. Whilst the evidence is limited and
> further
> research encouraged...what are we doing in the meantime re
> surveillance.
> Having moved away from glutaraldehyde 2 years ago we have done nothing
> further in this area and feel perhaps a lower level of surveillance is
> probably sufficient, ie self declaration questionnaires.Is anyone
> doing
> similar and what is the consensus of opinion?
>
> Christine Bouckley
> Occupational Health Nurse
> Calderdale and Huddersfield NHS Trust
> Halifax
> HX3 0PW
> Tel: 01422 222039
> e-mail: [log in to unmask]
>
>
> **********************************************************************
> This email and any files transmitted with it are confidential and
> intended solely for the use of the individual or entity to whom they
> are addressed. Any views or opinions presented are solely those of
> The author and do not necessarily represent those of the
> Trust unless explicitly stated otherwise. If you have received this
> e-mail in error please delete the e-mail and contact the
> Southampton University Hospitals NHS Trust Helpdesk on:-
>
> 023 80796000
>
> This footnote also confirms that this email message has been swept by
> MIMEsweeper for the presence of computer viruses.
> **********************************************************************
DISCLAIMER: This e-mail contains proprietary information some or all of
which may be confidential or legally privileged. It is for the exclusive use
of the intended recipient(s) only. If an addressing or transmission error
has misdirected this e-mail and you are not the intended recipient(s),
please notify the author by replying to this e-mail. If you are not the
intended recipient you must not use, disclose, distribute, copy, print, or
rely on this e-mail, as this may be unlawful.
|